|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06990 SKB BIO-B
Nominal 
235.800 +1.200 (+0.512%) Ranking Overview
Ranking based on 7 research report(s)
Average Ranking 2.00
|
Strong Buy (1)
0
|
Buy (2)
7
|
Hold (3)
0
|
Sell (4)
0
|
Strong Sell (5)
0
|
Previous Financial Performance
| Financial Year | 12/2023 | EPS | -284.00 RMB (cts) | |
| Net Profit | -574.13 RMB (MIL) | DPS | 0.00 RMB (cts) |
Consolidation Estimation
| Financial Year | Profit / (Loss) (RMB (MIL)) |
EPS/ ((LPS)(RMB (cts)) |
DPS (RMB (cts)) |
Net Asset Value per Share (RMB) |
Highest (RMB (MIL)) |
Lowest (RMB (MIL)) |
| 2024 | -246.00 | -110.00 | 0 | -- | 94.00 | -582.00 |
| 2025 | -747.00 | -321.00 | 0 | -- | -91.00 | -993.00 |
| 2026 | -406.00 | -179.00 | 0 | -- | 936.00 | -793.00 |
Profit Estimation
| Profit Estimation | Profit / (Loss) (RMB (MIL)) |
EPS*/ (LPS) (RMB (cts)) |
DPS * (RMB (cts)) |
Broker | Ranking | Target Price* (HKD) |
Update Date | |
| 2024 | -489.00 | -215.00 | -- | CICC | OutPerform | 277.00 | 01/03/2025 | |
| 2024 | -170.00 | -76.00 | -- | JP MORGAN | Overweight | 240.00 | 20/01/2025 | |
| 2024 | -582.00 | -261.00 | -- | HSBC | Buy | 237.00 | 29/11/2024 | |
| 2024 | 94.00 | 42.30 | -- | CLSA | OutPerform | 236.60 | 02/12/2024 | |
| 2024 | -278.00 | -125.00 | -- | UBS | Buy | 229.30 | 07/02/2025 | |
| 2024 | -246.00 | -110.00 | -- | CMB INT'L SEC | Buy | 227.88 | 13/01/2025 | |
| 2024 | -167.00 | -76.07 | -- | NOMURA | Buy | 211.87 | 17/02/2025 | |
| 2025 | -993.00 | -437.00 | -- | CICC | -- | -- | 01/03/2025 | |
| 2025 | -747.00 | -321.00 | -- | JP MORGAN | -- | -- | 20/01/2025 | |
| 2025 | -986.00 | -442.00 | -- | HSBC | -- | -- | 29/11/2024 | |
| 2025 | -251.00 | -112.80 | -- | CLSA | -- | -- | 02/12/2024 | |
| 2025 | -552.00 | -248.00 | -- | UBS | -- | -- | 07/02/2025 | |
| 2025 | -908.00 | -407.00 | -- | CMB INT'L SEC | -- | -- | 13/01/2025 | |
| 2025 | -91.00 | -41.56 | -- | NOMURA | -- | -- | 17/02/2025 | |
| 2026 | -406.00 | -179.00 | -- | CICC | -- | -- | 01/03/2025 | |
| 2026 | -677.00 | -290.00 | -- | JP MORGAN | -- | -- | 20/01/2025 | |
| 2026 | -793.00 | -356.00 | -- | HSBC | -- | -- | 29/11/2024 | |
| 2026 | 936.00 | 420.00 | -- | CLSA | -- | -- | 02/12/2024 | |
| 2026 | -314.00 | -141.00 | -- | UBS | -- | -- | 07/02/2025 | |
| 2026 | -787.00 | -353.00 | -- | CMB INT'L SEC | -- | -- | 13/01/2025 | |
| 2026 | 651.00 | 296.00 | -- | NOMURA | -- | -- | 17/02/2025 | |
| Remarks: | Average rating ranges from 1 to 5. The lower the figure, the higher the rating and the vice versa. |
| *EPS, DPS and Estimated Price would be adjusted upon Consolidation, Split and Bonus Issue | |
| Real time quote last updated: 04/03/2025 17:59 | |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 310,226 |
| %Change | -- |
| EPS / (LPS) | RMB 1.410 |
| NBV Per Share (¥) | RMB 14.401 |